Inactivation of the macrolide antibiotics erythromycin, midecamycin, and rokitamycin by pathogenic Nocardia species

Midecamycin Is Inactivated by Several Different Sugar Moieties at Its Inactivation Site

Glycosylation inactivation is one of the important macrolide resistance mechanisms. The accumulated evidences attributed glycosylation inactivation to a glucosylation modification at the inactivation sites of macrolides. Whether other glycosylation modifications lead to macrolides inactivation is unclear. Herein, we demonstrated that varied glycosylation modifications could cause inactivation of midecamycin, a 16-membered macrolide antibiotic used clinically and agriculturally. Specifically, an actinomycetic glycosyltransferase (GT) OleD was selected for its glycodiversification capacity towards midecamycin. OleD was demonstrated to recognize UDP-D-glucose, UDP-D-xylose, UDP-galactose, UDP-rhamnose and UDP-N-acetylglucosamine to yield corresponding midecamycin 2'-O-glycosides, most of which displayed low yields. Protein engineering of OleD was thus performed to improve its conversions towards sugar donors. Q327F was the most favorable variant with seven times the conversion enhancement towards UDP-N-acetylglucosamine. Likewise, Q327A exhibited 30% conversion enhancement towards UDP-D-xylose. Potent biocatalysts for midecamycin glycosylation were thus obtained through protein engineering. Wild OleD, Q327F and Q327A were used as biocatalysts for scale-up preparation of midecamycin 2'-O-glucopyranoside, midecamycin 2'-O-GlcNAc and midecamycin 2'-O-xylopyranoside. In contrast to midecamycin, these midecamycin 2'-O-glycosides displayed no antimicrobial activities. These evidences suggested that besides glucosylation, other glycosylation patterns also could inactivate midecamycin, providing a new inactivation mechanism for midecamycin resistance. Cumulatively, glycosylation inactivation of midecamycin was independent of the type of attached sugar moieties at its inactivation site.

Biotransformation of Bile Acids by Pathogenic Actinomycetes Nocardia otitidiscaviarum and Amycolatopsis sp. Strains

Three sterol-type compounds (compounds 4, 5 and 6) were isolated from culture broth of pathogenic Nocardia otitidiscaviarum IFM 0988 and Amycolatopsis sp. IFM 0703 strains which were isolated from Japanese patients. The structures of the compounds were determined by NMR and mass spectrometric analyses. The structural studies indicated that compound 4 is a biotransformation product from cholic acid derivative in a nutrient culture medium constituent by a reductase-type enzyme, and the remaining two compounds 5 and 6 are also biotransformation ones by oxidase-type enzymes.

Different rifampicin inactivation mechanisms in Nocardia and related taxa

Mycolic acid-containing bacteria inactivate rifampicin in a variety of ways such as glucosylation, ribosylation, phosphorylation and decolorization. These inactivations were found to be a species-specific phenomena in Nocardia and related taxa. Gordona, Tsukamurella and fast-growing Mycobacterium modified rifampicin by ribosylation of the 23-OH group of the antibiotic. Such ribosylation was not observed in Rhodococcus and Corynebacterium, but phosphorylation of the 21-OH group of rifampicin was observed in one strain of Rhodococcus. Nocardia modified the antibiotic by glucosylation (23-OH group) and phosphorylation, but ribosylation was not observed.

Pathogenic Nocardia isolated from clinical specimens including those of AIDS patients in Thailand

Forty strains of nocardioform microorganisms were isolated as clinical specimens including several from AIDS patients in Thailand. Among them, 37 strains were found to belong to the genus Nocardia. Our identification studies revealed that most of the strains (25 strains) belong to the N. asteroides group, i.e., N. asteroides sensu stricto and N. farcinica. Three strains were identified as N. otitidiscaviarum and two strains N. brasiliensis. In addition, 7 strains of rare pathogenic N. transvalensis were also isolated.

Ribosylation by mycobacterial strains as a new mechanism of rifampin inactivation

Several fast-growing Mycobacterium strains were found to inactivate rifampin. Two inactivated compounds (RIP-Ma and RIP-Mb) produced by these organisms were different from previously reported derivatives, i.e., phosphorylated or glucosylated derivatives, of the antibiotic. The structures of RIP-Ma and RIP-Mb were determined to be those of 3-formyl-23-[O-(alpha-D-ribofuranosyl)]rifamycin SV and 23-[O-(alpha-D-ribofuranosyl)]rifampin, respectively. To our knowledge, this is the first known example of ribosylation as a mechanism of antibiotic inactivation.